These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 16086421)

  • 1. How low is too low? Use of cluster analysis to define low levels of mercaptopurine metabolites.
    Traore F; O'Riordan MA; Myers C; Groth K; Hoff A; Angiolillo A; Rheingold S; Drotar D; Kodish E
    Pediatr Blood Cancer; 2006 Feb; 46(2):187-92. PubMed ID: 16086421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group).
    Bell BA; Brockway GN; Shuster JJ; Erdmann G; Sterikoff S; Bostrom B; Camitta BM;
    Pediatr Blood Cancer; 2004 Aug; 43(2):105-9. PubMed ID: 15236274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment adherence and 6-mercaptopurine metabolites.
    Gaynon PS
    Pediatr Blood Cancer; 2006 Feb; 46(2):120-1. PubMed ID: 16200555
    [No Abstract]   [Full Text] [Related]  

  • 4. Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia.
    Hawwa AF; Collier PS; Millership JS; McCarthy A; Dempsey S; Cairns C; McElnay JC
    Br J Clin Pharmacol; 2008 Dec; 66(6):826-37. PubMed ID: 18823306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiopurine S-methyltransferase (TPMT) gene polymorphism in Brazilian children with acute lymphoblastic leukemia: association with clinical and laboratory data.
    Silva MR; de Oliveira BM; Viana MB; Murao M; Romanha AJ
    Ther Drug Monit; 2008 Dec; 30(6):700-4. PubMed ID: 19057372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942).
    Jacobs SS; Stork LC; Bostrom BC; Hutchinson R; Holcenberg J; Reaman GH; Erdmann G; Franklin J; Neglia JP; Steinberg SM; Balis FM; Adamson PC; ;
    Pediatr Blood Cancer; 2007 Sep; 49(3):250-5. PubMed ID: 16856155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should TPMT genotype and activity be used to monitor 6-mercaptopurine treatment in children with acute lymphoblastic leukaemia?
    Fakhoury M; Andreu-Gallien J; Mahr A; Medard Y; Azougagh S; Vilmer E; Jacqz-Aigrain E
    J Clin Pharm Ther; 2007 Dec; 32(6):633-9. PubMed ID: 18021342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
    Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
    Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of oral 6-mercaptopurine: relationship between plasma levels and urine excretion of parent drug.
    Endresen L; Lie SO; Storm-Mathisen I; Rugstad HE; Stokke O
    Ther Drug Monit; 1990 May; 12(3):227-34. PubMed ID: 2349605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The low frequency of defective TPMT alleles in Turkish population: a study on pediatric patients with acute lymphoblastic leukemia.
    Tumer TB; Ulusoy G; Adali O; Sahin G; Gozdasoglu S; Arinç E
    Am J Hematol; 2007 Oct; 82(10):906-10. PubMed ID: 17617792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allopurinol Use During Maintenance Therapy for Acute Lymphoblastic Leukemia Avoids Mercaptopurine-related Hepatotoxicity.
    Giamanco NM; Cunningham BS; Klein LS; Parekh DS; Warwick AB; Lieuw K
    J Pediatr Hematol Oncol; 2016 Mar; 38(2):147-51. PubMed ID: 26808368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
    Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
    J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A step toward more accurate dosing for mercaptopurine in childhood acute lymphoblastic leukemia.
    Mulla H; Leary A; White P; Pandya HC
    J Clin Pharmacol; 2012 Oct; 52(10):1610-3. PubMed ID: 22174432
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetics of two 6-mercaptopurine liquid formulations in children with acute lymphoblastic leukemia.
    Tolbert JA; Bai S; Abdel-Rahman SM; August KJ; Weir SJ; Kearns GL; Neville KA
    Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28295989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and laboratory evaluation of compliance in acute lymphoblastic leukaemia.
    de Oliveira BM; Viana MB; Zani CL; Romanha AJ
    Arch Dis Child; 2004 Aug; 89(8):785-8. PubMed ID: 15269085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatotoxicity of 6-mercaptopurine in childhood acute lymphocytic leukemia: pharmacokinetic characteristics.
    Berkovitch M; Matsui D; Zipursky A; Blanchette VS; Verjee Z; Giesbrecht E; Saunders EF; Evans WE; Koren G
    Med Pediatr Oncol; 1996 Feb; 26(2):85-9. PubMed ID: 8531858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leucocyte versus erythrocyte thioguanine nucleotide concentrations in children taking thiopurines for acute lymphoblastic leukaemia.
    Lancaster DL; Patel N; Lennard L; Lilleyman JS
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):33-6. PubMed ID: 12111109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adolescent adherence to oral therapy for leukemia: a focus group study.
    Malbasa T; Kodish E; Santacroce SJ
    J Pediatr Oncol Nurs; 2007; 24(3):139-51. PubMed ID: 17475980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group Study L99-15.
    Manabe A; Ohara A; Hasegawa D; Koh K; Saito T; Kiyokawa N; Kikuchi A; Takahashi H; Ikuta K; Hayashi Y; Hanada R; Tsuchida M;
    Haematologica; 2008 Aug; 93(8):1155-60. PubMed ID: 18519521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: the FRALLE 93 study.
    Oudot C; Auclerc MF; Levy V; Porcher R; Piguet C; Perel Y; Gandemer V; Debre M; Vermylen C; Pautard B; Berger C; Schmitt C; Leblanc T; Cayuela JM; Socie G; Michel G; Leverger G; Baruchel A
    J Clin Oncol; 2008 Mar; 26(9):1496-503. PubMed ID: 18349402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.